BAX 855, a PEGylated rFVIII product with prolonged half-life: Development, functional and structural characterisation

Hamostaseologie

Volumn 32, Issue SUPPL. 1, 2012, Pages

  Turecek, P L ^a   Bossard, M J ^b   Graninger, M ^a   Gritsch, H ^a   Hollriegl W ^a   Kaliwoda, M ^a   Matthiessen, P ^a   Mitterer, A ^a   Muchitsch, E M ^a   Purtscher, M ^a   Rottensteiner, H ^a   Schiviz, A ^a   Schrenk, G ^a   Siekmann, J ^a   Varadi, K ^a   Riley, T ^b   Ehrlich, H J ^a   Schwarz, H P ^a   Scheiflinger, F ^a  

^a BAXTER INNOVATIONS GMBH   (Austria)

^b NEKTAR THERAPEUTICS   (United States)

Author keywords

Haemophilia; Peg; Recombinant factor VIII; Substitution therapy

Indexed keywords

BAX 855; MACROGOL; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC);

EID: 84873625664     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1619772     Document Type: Article

References (33)

1. MASAC Recommendation Concerning Prophylaxis (Prophylactic Administration of Clotting Factor Concentrate to Prevent Bleeding). 3-8-2007. National Hemophilia Foundation. www.hemo philia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid= 5&contentid=349
2. MASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). 11-4-2007. National Hemophilia Foundation. www.hemophilia.org/ NHFWeb/MainPgs/MainNHF.aspx?menuid= 5&contentid=349
3. Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients--a longterm follow-up. J Intern Med 1997; 241: 395-400.
4. Royal S, Schramm W, Berntorp E et al. Quality-oflife differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 2002; 8: 44-50.
5. Hoots WK, Nugent DJ. Evidence for the benefits of prophylaxis in the management of hemophilia A. Thromb Haemost 2006; 96: 433-440.
6. Manco-Johnson M. Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice. Haemophilia 2007; 13 (Suppl 2): 4-9.
7. Roosendaal G, Lafeber F. Prophylactic treatment for prevention of joint disease in hemophilia--cost versus benefit. N Engl J Med 2007; 357: 603-605.
8. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-4654.
9. Morado M, Villar A, Jimenez-Yuste V et al. Prophylactic treatment effects in inhibitor risk: experience in one centre. Haemophilia 2005; 11: 79-83.
10. Lee CA. Prevention of haemophilic synovitis: prophylaxis. Haemophilia 2007; 13 (Suppl 3): 20-25.
11. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for se-S38 P. L. Turecek et al.: BAX 855 Hämostaseologie 4a/2012 © Schattauer 2012 vere factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-399.
12. Manco-Johnson MJ, Nuss R, Geraghty S et al. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 1994; 47: 113-117.
13. Fischer K, van der Bom JG, Molho P et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and longterm outcome. Haemophilia 2002; 8: 745-752.
14. Berntorp E Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens. Haemophilia 2009; 15: 1219-1227.
15. Björkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001; 40: 815-832.
16. Björkman S, Folkesson A, Jonsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: A population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 2009; 65: 989-998.
17. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003; 2: 214-221.
18. Riley T, Riggs-Sauthier J. The benefits of challenges of PEGylating small molecules. Pharm Tech 2008; 32: 1-5.
19. Bovenschen N, Boertjes RC, van Stempvoort G et al. Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII. J Biol Chem 2003; 278: 9370-9377.
20. Bovenschen N, van Stempvoort G, Voorberg J et al. Proteolytic cleavage of factor VIII heavy chain is required to expose the binding site for low-density lipoprotein receptor-related protein within the A2 domain. J Thromb Haemost 2006; 4: 1487-1493.
21. Bovenschen N, Mertens K, Hu L et al. LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo. Blood 2005; 106: 906-912.
22. Mei B, Pan C, Jiang H et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116: 270-279.
23. Rottensteiner H, Turecek PL, Meijer AB et al. The prolonged half-life of PEGylated and polysialylated FVIII in murine models might be caused by a reduced binding to the LRP1 receptor. 52. Jahres -tagung der Gesellschaft für Thrombose- und Hämostase forschung e.V. February 20-23, 2008, Wiesbaden, Germany.
24. Monetti C, Rottensteiner H, Gritsch H et al. Structural analysis of the recombinant therapeutic product rFVIII and its PEGylated variants using 2-D DIGE. Electrophoresis 2011; 32: 1292-1301.
25. Elödi S, Váradi K, Vörös E. Kinetic of formation of factor IXa - factor VIII complex on the surface of platelets. Thromb Res 1981; 21: 695-700.
26. Fay PJ. Regulation of factor VIIIa in the intrinsic factor Xase. Thromb Haemost 1999; 82: 193-200.
27. Fay PJ, Smudzin TM, Walker FJ. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem 1991; 266: 20139-20145.
28. Koedam JA, Meijers JC, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 1988; 82: 1236-1243.
29. Gilbert GE, Furie BC, Furie B. Binding of human factor VIII to phospholipid vesicles. J Biol Chem 1990; 265: 815-822.
30. Muchitsch EM, Turecek PL, Zimmermann K et al. Phenotypic expression of murine hemophilia. Thromb Haemost 1999; 82: 1371-1373.
31. Bi L, Lawler AM, Antonarakis SE et al. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia. A. Nat Genet 1995; 10: 119-121.
32. Furie B, Furie BC. Thrombus formation in vivo. J Clin Invest 2005; 115: 3355-3362.
33. Bendetowicz AV, Wise RJ, Gilbert GE. Collagenbound von Willebrand factor has reduced affinity for factor VIII. J Biol Chem 1999; 274: 12300-12307.